Source: Virtual Congress 2021 – Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
C. Magis-Escurra (Nijmegen, Netherlands). Has the time come to shorten TB treatment and TB preventive therapy?. Virtual Congress 2021 – Respiratory infections

Member's Comments

No comment yet.

Related content which might interest you: On abandon of the tuberculosis treatment Source: Eur Respir J 2003; 22: Suppl. 45, 522s Year: 2003 Early experience with the implementation of the WHO shorter MDR-TB treatment regimen in Singapore Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Do we need to screen for latent TB when initiating a methotrexate treatment? Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013 Outcome of drug resistant TB in hospital settings-a comparision of individualized treatment based on past history of anti-TB drugs with culture sensitivity guided treatment Source: Eur Respir J 2006; 28: Suppl. 50, 589s Year: 2006 A comparison of on-site versus remote physician follow up of directly observed preventive treatment (DOPT) for latent tuberculosis infection (LTBI) on completion rates Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II Year: 2012 Experience of isofon use for therapy and chemoprophylaxis of tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 486s Year: 2004 Should we treat every patient with latent TB? Is there a cost to pay? Source: International Congress 2018 – Tuberculosis transmission and screening strategies Year: 2018 How did the tuberculosis patients reach to a tuberculosis dispensary and how long did it take? Source: Annual Congress 2011 - Challenges in tuberculosis control Year: 2011 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 A novel nurse-led approach improves treatment completion rates for latent tuberculosis infection (LTBI) treatment Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches Year: 2014 Choice and adherence in preventive treatment for tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003 Is DOTS-Plus effective and cost-effective? Source: Annual Congress 2007 - PG18 - New challenges in fighting tuberculosis in Europe Year: 2007 Directly observed therapy versus self administered therapy for patients of new smear positive pulmonary tuberculosis during hospitalisation period Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004 Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis? Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis Year: 2008 A choice of regimen improves completion for patients with latent TB infection Source: Breathe 2008; 4: 366 Year: 2008 The effectiveness of the treatment of patients with TB in the condition adapted DOTS-strategy in Ukraine Source: Annual Congress 2008 - Outcomes of tuberculosis treatment Year: 2008 How soon does tuberculosis in HIV infected patients respond to anti-tuberculous treatment? Source: Annual Congress 2010 - Tuberculosis and HIV coinfection Year: 2010 Impact of smoking on outcome of treatment of tuberculosis in patients taking intermittent treatment of tuberculosis under India‘s revised tuberculosis control program Source: Annual Congress 2008 - Health effects of passive smoking and of a smoking ban Year: 2008 Long term treatment out come in multi drug resistant tuberculosis Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010